Zh.E. Komekbay¹, G.A. Temirova¹

1. «West Kazakhstan Marat Ospanov State Medical University» NCJSC, Aktobe, the Republic of Kazakhstan

DOI: https://www.doi.org/10.52532/2521-6414-2024-1-71-22-29

UDC: 616.33-006.6-091.8-071

Year: 2024 issure: 71 number: 1 pages: 22-29

Download PDF:

ABSTRACT

Relevance: Gastric cancer continues to lead the cancer incidence structure. One of the directions of a comprehensive plan to reduce the incidence of malignant neoplasms is the development a highly efficient early diagnostics based on the relationship between the expression of the cell proliferation marker Ki-67 in gastric cancer with age, sex, stage of the disease and the degree of tumor differentiation according to immunohistochemical analysis.
The study aimed to study the relationship between the expression of the Ki-67 marker in gastric cancer and age, sex, stage of the disease, and the degree of tumor differentiation.
Methods: The research design is a comparative descriptive study. For the study, surgical material was used from 109 patients with gastric cancer stages 0-IIIC, obtained during gastric cancer operations from the pathology department of the West Kazakhstan Marat Ospanov Medical University (WKMOMU) Medical Center from 2021 to 2022. Histological and immunohistochemical studies were conducted at the morphological laboratory of the Department of Histology of WKMOMU. The obtained data was statistically processed.
Results: The present study showed a significant statistical correlation between the Ki-67 level and the histopathological grade of gastric cancer (p=0.039).
The indicators such as ‘pTNM stage’ (p=0.894), ‘Age’ (p=0.664), ‘Sex (F – 1, M – 2)’ (p=0.928), and ‘Tumor localization (cardiac – 1, body – 2, antral and pyloric – 3)’ (p=0.866) did not statistically significantly correlated with the Ki-67 expression level.
Conclusion: The relationship between Ki-67 expression and histopathological grade (p=0.039) in gastric cancer helps identify patients with aggressive tumors that require adjuvant therapy.
Keywords: gastric cancer, morphology, histology, immunohistochemistry, Ki 67, proliferation.

List of sources used:

1. Тасжанов Р.С., Игисинов Н.С., Кожахметов С.К., Кобландин С., Игисинова Г.С., Билялова З.A., Кульмирзаева Д.M. Динамика некоторых показателей онкологической служ-бы при раке желудка в Казахстане // Медицина (Алматы). – 2020. – № 1-2 (211-212). – С. 21-25 [Taszhanov R.S., Igisinov N.S., Kozhahmetov S.K., Koblandin S., Igisinova G.S., Biljalova Z.A., Kul’mirzaeva D.M. Dinamika nekotoryh pokazatelej onkologicheskoj sluzhby pri rake zheludka v Kazahstane. Medicina (Almaty). – 2020. – № 1-2 (211-212). – S. 21-25 (in Russ.)]. https://doi.org/10.31082/1728-452X-2020-211-212-1-2-21-25
2. International Agency for Research on Cancer. Global Cancer Observatory. Stomach Fact Sheet. https://gco.iarc.who.int/media/globocan/factsheets/cancers/7-stomach-fact-sheet.pdf
3. Михалёва Л.М., Бирюков А.Е., Полянко Н.И. Предраковые поражения и ранний рак желудка: современные клинико-морфологические данные // Клиническая медицина. – 2017. – №95(100). – С. 881-887 [Mixaleva L.M., Biryukov A.E., Polyanko N.I. Precancerous lesions and early gastric cancer: modern clinical-morphological data // Clinical medicine. – 2017. – №95(100). – S. 881-887 (in Russ.)]. https://cyberleninka.ru/article/n/ predrakovye-porazheniya-i-ranniy-rak-zheludka-sovremennye-kliniko-morfologicheskie-dannye
4. Жылкайдарова А.Ж. Оценка динамики показателей заболеваемости и смертности от рака желудка в Казахстане за 2004-2014 годы // Онкология и радиология Казахстана. – 2017. – №1(43). – С. 12-20 [Jylkaıdarova A. J. Otsenka dınamıkı pokazateleı zabolevaemostı ı smertnostı ot raka jelýdka v Kazahstane za 2004-2014 gody // Onkologııa ı radıologııa Kazahstana.–2017.–№5(43).–S.12-20 (in Russ.)]. https://oncojournal.kz/docs/2017. 1.43_02.pdf
5. Об утверждении комплексного плана по борьбе с онкологическими заболеванияами в Республике Казахстан на 2018-2022 годы. Пост-е Прав-ва Республики Казахстан от 29 июня 2018 года №395, с изм. по сост. на 29.12.2020 [Ob utverzhdenii Kompleksnogo plana po bor’be s onkologicheskimi zabolevaniyami v Respublike Kazaxstan na 2018-2022 gody. Post-e Prav-va Respubliki Kazaxstan ot 29 iyunya 2018 goda №395, s izm. po sost. na 29.12.2020 (in Russ.)]. https://online.zakon.kz/Document/?doc_id=35255787&pos=4;-88#pos=4;-88
6. Об утверждении Комплексного плана по борьбе с онкологическими заболеваниями в Республике Казахстан на 2023-2027 годы. Пост-е Прав-ва Республики Казахстан от 5 октября 2023 года № 874 [Ob ýtverjdenıı Kompleksnogo plana po borbe s onkologıcheskımı zabolevanııamı v Respýblıke Kazahstan na 2023-2027 gody. Post-e Prav-va Respublıkı Kazahstan ot 5 oktyabrya 2023 goda № 874 (in Russ.)]. https://adilet.zan.kz/rus/docs/P2300000874
7. Сатханбаев А.З., Тажимурадов Р.Т., Жанабаев Н.С., Аннаоразов Ы.А., Ілес Н.Т., Тагаров У.Х., Ескендіров Б.Б. эффективности применения комплексных методов исследовании для выявления в ранних признаков малигнизации при предраковых заболеваниях желудка // Вестник КазНМУ. – 2019. – №1. – С. 128-132 [Sathanbaev A.Z., Tazhimuradov R.T., Zhanabaev N.S., Annaorazov Y.A., Iles N.T., Tagarov U.H., Eskendirov B.B. //Mezhdunarodnyj Kazahsko-Tureckij universitet im. H.A.Yassavi effektivnosti primeneniya kompleksnyh metodov issledovanii dlya vyyavleniya v rannih priznakov malignizacii pri predrakovyh zabolevaniyah zheludka // Vestnik KazNMU. – 2019. – №1. – S. 128-132 (in Russ.)]. https://kaznmu.kz/press/wp-content/uploads/2019/04/Вестник-КазНМУ-№1-2019-3.pdf
8. Ye D.M., Xu G., Ma W., Li Y., Luo W., Xiao Y., Liu Y., Zhang Z. Significant function and research progress of biomarkers in gastric cancer (Review) // Oncol. Let. – 2019. – Vol. 19(1). ­– P. 17-29. https://doi.org/10.3892%2Fol.2019.11078
9. Мыльников А.Г., Климов А.Е., Курбанниёзов Т.Ш., Буйместру Н.В., Черняева А.А., Гусарова Т.А. Экстренная тотальная дуоденопанкреатэктомия по поводу профузного желудочно-кишечного кровотечения, вызванного метастазами рака почки в поджелудочную железу // Вестник РУДН. Серия: Медицина. – 2023. – Т. 27, №2. – C. 246-253 [Mylnikov A.G., Klimov A.E., Kurbanniyozov T.Sh., i dr. Ekstrennaya totalnaya duodenopankreatektomiya po povodu profuznogo zheludochno-kishechnogo krovotecheniya, vyzvannogo metastazami raka pochki v podzheludochnuyu zhelezu // Vestnik RUDN. Seriya: Medicina. – 2023. – T. 27, №2. – C. 246-253 (in Russ.)]. https://doi.org/10.22363/2313-0245-2023-27-2-246-253.
10. Луньков А.Е., Гладилин Ю.А., Ибрагимова К.Е. Исследование зависимости размеров измеряемых микроскопических объектов от положения плоскости среза // Морфологические ведомости. – 2019. – №27(4). – С. 55-60 [Lunkov A.E., Gladilin Yu.A., Ibragimova K.E. // Issledovanie zavisimosti razmerov izmeryaemyh mikroskopicheskih obektov ot polozheniya ploskosti sreza. Morfologicheskie vedomosti. – 2019. – №27(4). – S. 55-60 (in Russ.)]. https://doi.org/10.20340/mv-mn.19(27).04.55-60.
11. Мозеров С.A., Комин Ю.A., Мозерова Е.С. и др. Иммуногистохимия против степени патоморфоза злокачественных новообразований // Здоровье и образование в XXI веке. – 2016. – Т.18, №11. – С. 108-116 [Mozerov S.A., Komin Yu.A., Mozerova E.S. i dr. Immunogistoximiya v ocenke stepeni patomorfoza zlokachestvennyx novoobrazovanij. Zdorov’e i obrazovanie v XXI veke. – 2016. – Т. 18, №1. – S. 108-116 (in Russ.)]. https://cyberleninka.ru/article/n/immunogistohimiya-v-otsenke-stepeni-patomorfoza-zlokachestvennyh-novoobrazovaniy
12. Sitarz R., Skierucha M., Mielko J., Offerhaus G.J.A., Maciejewski R., Polkowski W.P. Gastric cancer: epidemiology, prevention, classification, and treatment // Cancer Manag. Res. – 2018. – Vol. 10. – P. 239-248. https://doi.org/10.2147/CMAR.S149619
13. Liu F., Wu X., Wang W., Chang J. A novel immunohistochemical score predicts the postoperative prognosis of gastric cancer patients // World J. Surg. Oncol. – 2023. – №21(1). – Art. no. 220. https://doi.org/10.1186/s12957-023-03113-7
14. Ko G.H., Go S.I., Lee W.S., Lee J.H., Jeong S.H., Lee Y.J., Hong S.C., Ha W.S. Prognostic impact of Ki-67 in patients with gastric cancer-the importance of depth of invasion and histologic differentiation // Medicine (Baltimore). – 2017. – Vol. 96(25). – Art. no. e7181. https://doi.org/10.1097/MD.0000000000007181
15. Solhjoo M., Haghi A.R., Golchin N., Golchin N., Shanbazi R. Expression of E-cadherin and Ki-67 in Gastric Cancer Patients and Correlation with Clinicopathological Factors // Mathews J. Cancer Sci. – 2018. – Vol. 3(1). – Art. no. 015. https://www.mathewsopenaccess.com/full-text/expression-of-e-cadherin-and-ki-67-in-gastric-cancer-patients-and-correlation-with-clinicopathological-factors
16. Pranjali C., Sulatha K., Vijaya V.M. CDX2 and Ki-67 Expression in Gastric Carcinoma and Its Association with Clinocopathological Parameters // Asian Pac. J. Cancer Biol. – Vol. 7 (3). – P. 255-263. https://doi.org/10.31557/apjcb.2022.7.3.255-263.
17. El-Gendi S., Talaat I., Abdel-Hadi M. HER-2/Neu Status in Gastric Carcinomas in a Series of Egyptian Patients and Its Relation to Ki-67 Expression // Open J. Pathol. – 2015. – Vol. 5 (4). – P.101-113. http://dx.doi.org/10.4236/ojpathology.2015.54014.
18. Luo G., Hu Y., Zhang Z., Wang P., Luo Z., Lin J., Cheng C., Yang Y. Clinicopathologic significance and prognostic value of Ki-67 expression in patients with gastric cancer: a meta-analysis // Oncotarget. – 2017. – Vol. 8(30). – P. 50273-50283. https://doi.org/10.18632/oncotarget.17305
19. Almabrouk N.M., El-Maraghy M.N.E., Mohy Eldin Badr A., Meckawy G.R., Shakweer M.M. Prognostic utility of Ki-67 in gastric carcinoma // Immunopathol. Persa. – 2022. – Vol. 8 (1). – Art. no. e14. https://pdfs.semanticscholar.org/c462/e6d32205fd2726f14a32a36e7d886728 fd58.pdf